Aspirin – Medxy AI

Aspirin vs. Clopidogrel Monotherapy Following PCI: Insights from the STOPDAPT-3 1-Year Follow-up

By MedXY 09/22/2025

The STOPDAPT-3 trial compared aspirin and clopidogrel monotherapy after short dual antiplatelet therapy in PCI patients, showing similar cardiovascular and bleeding outcomes at 1 year.

Clinical Updates Wellness & Lifestyle

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Clinical Updates Wellness & Lifestyle

Aspirin for Delaying Preterm Birth in High-Risk Preterm Pre-eclampsia Pregnancies: Insights from a Multicenter Randomized Trial in Asia

By MedXY 09/19/2025

Early low-dose aspirin reduces early preterm birth risk and delays timing of delivery in women at high risk for preterm pre-eclampsia, with significant benefits in iatrogenic preterm births and small-for-gestational-age pregnancies.

Clinical Updates Wellness & Lifestyle

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY 09/19/2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost-effective adjuvant strategy.

Clinical Updates Wellness & Lifestyle

Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial

By MedXY 09/19/2025

This randomized trial confirms that daily low-dose aspirin significantly reduces colorectal cancer recurrence in patients with PI3K pathway mutations, highlighting a targeted adjunctive therapy option.

Clinical Updates Wellness & Lifestyle

Clopidogrel Surpasses Aspirin: Comprehensive Meta-Analysis Shows Superior Secondary Prevention in Coronary Artery Disease

By MedXY 09/02/2025

A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.

Clinical Updates Wellness & Lifestyle

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

By MedXY 08/21/2025

Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.

Clinical Updates Wellness & Lifestyle

Mechanical Thrombectomy in Distal Medium MCA Occlusion: Impact of Pre-Stroke Low-Dose Aspirin on Efficacy and Safety

By MedXY 08/17/2025

Pre-stroke low-dose aspirin in distal medium vessel occlusion stroke patients undergoing mechanical thrombectomy is linked to improved 90-day functional outcomes and reduced mortality without increased symptomatic hemorrhage risk.

Clinical Updates Wellness & Lifestyle

Evaluating Aspirin Plus Rivaroxaban versus Rivaroxaban Alone to Prevent Venous Stent Thrombosis in Post-Thrombotic Syndrome: Insights from the ARIVA Trial

By MedXY 08/17/2025

The ARIVA trial found no superior benefit of adding aspirin to rivaroxaban over rivaroxaban alone in preventing venous stent thrombosis within 6 months post-intervention in post-thrombotic syndrome patients, with both regimens showing high patency and safety.